Literature DB >> 12797542

Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Petar Lenert1, Adam Goeken, Barry S Handwerger, Robert F Ashman.   

Abstract

Inadequate immune response to infectious danger may contribute to the pathogenesis of systemic autoimmune diseases, e.g., systemic lupus erythematosus. To test this hypothesis, we studied innate responses of prediseased lupus-prone Palmerston North (PN) mice to lipopolysaccharide (LPS), bacterial DNA, and synthetic CpG oligonucleotides. LPS and bacterial DNA/CpG oligodeoxyribonucleotides (ODNs) drove PN splenocytes into the cell cycle and protected B cells against spontaneous apoptosis, as in control lupus-free DBA-1 mice. LPS induced significantly higher IL-6 production in PN than in control splenocytes. In contrast, in PN splenocytes bacterial DNA and CpG ODNs induced approximately four- to sixfold lower IL-12p40 and approximately twofold lower IL-6 secretion than controls. This reduction in cytokine secretion in PN mice was not due to delayed kinetics but was related to significantly higher constitutive and CpG-inducible IL-10 secretion. Neutralizing anti-IL-10 antibodies almost completely restored PN IL-6 and IL-12p40 secretion to DBA-1 levels, whereas exogenous IL-10 inhibited in vitro IL-6 and IL-12p40 production in DBA-1 mice. Importantly, treatment with either IL-10 or anti-IL-10 antibody did not modulate CpG-induced cell cycle entry and apoptosis protection in either strain. In conclusion, lupus-prone PN mice show abnormal innate responses through their pattern-recognition TLR9 receptors, characterized by higher inducible IL-10 and lower IL-12p40 and IL-6 secretion, thus implying that response to infectious danger in PN mice is inappropriate and may be linked to lupus pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797542     DOI: 10.1023/a:1023361912950

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  60 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs.

Authors:  Y Chen; P Lenert; R Weeratna; M McCluskie; T Wu; H L Davis; A M Krieg
Journal:  Gene Ther       Date:  2001-07       Impact factor: 5.250

3.  Different Toll-like receptor agonists induce distinct macrophage responses.

Authors:  B W Jones; T K Means; K A Heldwein; M A Keen; P J Hill; J T Belisle; M J Fenton
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

4.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

5.  Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells.

Authors:  I G Luzina; R H Knitzer; S P Atamas; W C Gause; J C Papadimitriou; M B Sztein; C E Storrer; B S Handwerger
Journal:  Arthritis Rheum       Date:  1999-03

6.  Macrophages ingest and are activated by bacterial DNA.

Authors:  K J Stacey; M J Sweet; D A Hume
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

7.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

Authors:  L Llorente; Y Richaud-Patin; C García-Padilla; E Claret; J Jakez-Ocampo; M H Cardiel; J Alcocer-Varela; L Grangeot-Keros; D Alarcón-Segovia; J Wijdenes; P Galanaud; D Emilie
Journal:  Arthritis Rheum       Date:  2000-08

8.  IL-10 up-regulates human monocyte phagocytosis in the presence of IL-4 and IFN-gamma.

Authors:  F Capsoni; F Minonzio; A M Ongari; V Carbonelli; A Galli; C Zanussi
Journal:  J Leukoc Biol       Date:  1995-09       Impact factor: 4.962

9.  Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood.

Authors:  E Hagiwara; M F Gourley; S Lee; D K Klinman
Journal:  Arthritis Rheum       Date:  1996-03

10.  Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA.

Authors:  G S Gilkeson; P Ruiz; A M Pippen; A L Alexander; J B Lefkowith; D S Pisetsky
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

2.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

Review 3.  Autoantibodies in systemic lupus erythematosus.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2011-12-23       Impact factor: 3.651

Review 4.  Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.

Authors:  Petar S Lenert
Journal:  Arthritis Res Ther       Date:  2006-01-10       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.